Welcome to our dedicated page for Aptinyx news (Ticker: APTX), a resource for investors and traders seeking the latest updates and insights on Aptinyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptinyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptinyx's position in the market.
Aptinyx Inc. (Nasdaq: APTX) announced the promotion of Andy Kidd to the role of president and chief operating officer, effective December 14, 2020. Kidd, who has been with the company since 2017 as chief commercial officer and COO, has a strong track record in the industry, including prior roles at Baxter International. His expanded leadership role is expected to enhance Aptinyx's capabilities as the company continues to focus on developing therapies for neurological disorders using its proprietary NMDA receptor modulation technology.
Aptinyx Inc. (Nasdaq: APTX) reported its Q3 2020 financial results, highlighting significant advancements in clinical trials for NMDA receptor modulators despite challenges posed by COVID-19. The company resumed its fibromyalgia study and reported positive outcomes in a PTSD Phase 2 study, validating its therapeutic approach. Financially, Aptinyx completed a $48.3 million stock offering, bolstering its cash position to approximately $148 million, which supports operations into 2023. The firm aims to achieve key milestones in its clinical pipeline, including future studies for NYX-2925 and NYX-783.
Aptinyx Inc. (Nasdaq: APTX) announced participation in two investor conferences. A presentation at the Stifel 2020 Virtual Healthcare Conference is scheduled for November 17, 2020, at 1:20 p.m. ET. Additionally, a pre-recorded fireside chat will be available during the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020, accessible on the company’s IR website. Aptinyx focuses on developing therapies for brain and nervous system disorders, with three product candidates in clinical development for conditions like chronic pain and PTSD.
Aptinyx Inc. (Nasdaq: APTX) announced a conference call on November 12, 2020, at 5:00 p.m. ET to discuss its third quarter financial results and business highlights. The call can be accessed domestically at (833) 772-0394 and internationally at (236) 738-2205 using conference ID 9186375. The company is focused on developing therapies for brain and nervous system disorders and has three candidates in clinical development targeting chronic pain, PTSD, and cognitive impairment linked to Parkinson's disease.
Aptinyx Inc. (Nasdaq: APTX) has completed a public offering of 16,100,000 shares of common stock at $3.00 per share, totaling $48.3 million in gross proceeds. The offering included an exercised option for additional shares and was managed by SVB Leerink, Piper Sandler, and Cantor. The proceeds will fund the development of novel NMDA receptor modulators targeting chronic pain, PTSD, and cognitive impairments. The shares were issued under an effective shelf registration statement with the SEC.
Aptinyx Inc. (Nasdaq: APTX) has announced the pricing of its public offering of 14,000,000 shares at $3.00 per share, aimed at raising $42.0 million before deductions. The offering is expected to close on October 26, 2020 and includes a 30-day option for underwriters to purchase an additional 2,100,000 shares. The proceeds will be utilized to advance the development of NMDA receptor modulators targeting chronic pain, PTSD, and cognitive impairment, as well as for working capital. The offering is registered with the SEC.
Aptinyx Inc. (Nasdaq: APTX) announced its intention to offer 12,000,000 shares of common stock in an underwritten public offering, with an option for underwriters to purchase an additional 1,800,000 shares. The offering aims to fund the development of its NMDA receptor modulators, including NYX-2925, NYX-783, and NYX-458, targeted for chronic pain, PTSD, and cognitive impairment. The shares will be issued under a previously filed shelf registration statement. The offering's completion is subject to market conditions.
Aptinyx Inc. (Nasdaq: APTX) announced positive results from its Phase 2 study of NYX-783 for PTSD, demonstrating statistically significant efficacy. In a randomized trial involving 153 patients, both 10 mg and 50 mg doses showed meaningful improvements on the CAPS-5 scale, while the 50 mg dose group reported 78% achieving a 30% improvement from baseline. The study indicated that NYX-783 was well tolerated with a favorable adverse event profile, prompting the company to plan a pivotal study in 2021, suggesting strong potential for addressing unmet needs in PTSD treatment.
Aptinyx Inc. (Nasdaq: APTX) announced the reactivation of study sites and resumption of patient recruitment in its Phase 2 study of NYX-2925 for fibromyalgia, paused since March 2020 due to COVID-19. This randomized, double-blind, placebo-controlled trial aims to enroll approximately 300 patients, evaluating the drug's efficacy and safety over 12 weeks. Preliminary positive results from earlier studies have bolstered confidence in the drug’s potential. Data is anticipated in the first half of 2022.
Aptinyx Inc. (Nasdaq: APTX) announced on June 18, 2020, the completion of enrollment in its Phase 2 exploratory study of NYX-783, aimed at evaluating its safety and efficacy for treating post-traumatic stress disorder (PTSD). The study includes 160 patients randomized into three treatment arms and will assess changes in PTSD symptoms over a 10 to 13-week period. Preliminary data is expected to be reported in late 2020, marking a crucial milestone in Aptinyx's development efforts, particularly during the challenges posed by the COVID-19 pandemic.
